HOME >> BIOLOGY >> NEWS
Pioneering experiments testing effects of greenhouse gases on crops

CHAMPAIGN, Ill. Portions of 40 acres of University of Illinois farmland this summer are sprouting soybeans grown in the presence of carbon dioxide levels forecast for the year 2050. Next summer, elevated levels of ozone will join the mix in a first-of-its-kind experiment called SoyFACE.

"When you consider the importance of the Midwest in terms of global food security, it is important to do this research here," said Stephen P. Long, a photosynthesis expert and the Robert Emerson Professor of Plant Biology at the UI. "Up to now, experiments related to global warming on many crops have been done in locations on the periphery of major food production areas."

Researchers want to know how soybeans may be affected, and what scientists might do to assure the integrity of yields and quality as the climate changes. By 2050, carbon dioxide levels are expected to be about 1.5 times greater than the current 370 parts per million, while daytime ozone levels during the growing season could peak on average at 80 parts per billion (now 60 parts per billion).

SoyFACE (Free Air gas Concentration Enrichment) is the first test of crop growth in the presence of both increased carbon dioxide and ozone. Five UI departments, the USDA-ARS and Illinois State Water Survey, as well as researchers from four other nations and two other U.S. universities are participating this summer.

Four control and four experimental 70-foot-diameter rings currently surround 24 varieties of soybeans. The experimental rings have ABS plastic pipes that deliver at crop level a precisely regulated flow of carbon dioxide, based on wind speed and direction, pumped from a 50-ton solar-powered tank.

Next summer, soybeans will grow on an adjacent 40 acres dotted with 24 of the octagon-shaped rings. Four rings will pump carbon dioxide, four will provide just ozone and four will provide ozone and carbon dioxide. Natural conditions will exist in an equal number of control rings for each test
'"/>

Contact: Jim Barlow
b-james3@uiuc.edu
217-333-5802
University of Illinois at Urbana-Champaign
2-Jul-2001


Page: 1 2

Related biology news :

1. Pioneering AIDS researcher to speak at UH
2. Pioneering discoveries, pursuing new knowledge, fostering partnerships
3. Pioneering flu researcher wins major Imperial scientific award
4. Pioneering study compares 13 vertebrate genomes
5. UFS Mcknight Brain Institute researchers: Pioneering spinal cord procedure appears safe
6. Pioneering evolutionist Ledyard Stebbins dies at age 94
7. Pioneering Research Could Lead To Treatment
8. Sandia experiments may reduce possibility of future water wars
9. APS recognizes Intel high school finalists for experiments in physiology
10. BioScience seeks nominations of beauteous experiments
11. ALife experiments show how complex functions can evolve

Post Your Comments:
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: